DB Schenker Korea receives IATA CEIV pharma certification

  • Share on Facebook
  • Share on Twitter
  • Share on Linkedin
  • Share on Pinterest
  • Share on Blogger

July 5, 2019: Schenker Korea has been accredited with the IATA CEIV pharma certification, recognising the company for its commitment to ensuring product integrity and the safety of healthcare products via air freight.

The award ceremony, organised by IATA Korea, took place on June 3 at the IATA Annual General Meeting and World Air Transport Summit in Seoul. The certificate was presented by Alexandre de Juniac, director general and CEO of IATA, to Schenker Korea CEO Dirk Lukat.

The Center of Excellence for Independent Validators in Pharmaceutical Logistics, or CEIV Pharma, is an IATA programme designed to address the pharmaceutical industry’s need for increased safety, security, compliance and efficiency, through the creation of a globally consistent pharmaceutical product-handling certification. 

Hanmin Kim, head of air freight Schenker Korea, commented that the certification is an official recognition of Schenker Korea’s pharmaceutical transportation and operational capabilities. 

In January 2018, the Incheon Airport CEIV Pharma Committee was formed through the initiative of Schenker Korea by the Incheon International Airport Corporation (IIAC), with the objective of verifying end-to-end logistics processes, from the point of arrival of goods, up until the final delivery. This partnership required a strong collaboration between IIAC, Korean Airlines, Asiana Airlines, and DB Schenker. 

In July 2018, IATA conducted a two-week CEIV Pharma training with more than 30 representatives from the 4 participating organisations. The training was followed by a preliminary assessment in August 2018 held by IATA validators. From there, further preparation and validation ensued until the successful audit in May 2019.a

  • Share on Facebook
  • Share on Twitter
  • Share on Linkedin
  • Share on Pinterest
  • Share on Blogger